Camallergy awarded £1.1m funding under Innovate UK Biomedical Catalyst Award for novel peanut allergy treatment  

- Funding will accelerate development for proprietary treatment for peanut allergy 

- Company to provide corporate update at upcoming Global Life Sciences investor conference 

CAMBRIDGE, UK – 23 March 2021 – Cambridge Allergy Ltd (“Camallergy” or “the Company”), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded £1.1m funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency.    

The £1.1m in non-dilutive funding will be used to accelerate the Company’s peanut allergy immunotherapy, CA002, for planned Phase 3 clinical trials. The project commences in the first quarter of 2021, and as part of the project’s success, the Company intends to file its investigation new drug application with the FDA and submit a clinical trials application to the MHRA and EMA. 

“This innovation award is further testament to Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy,” said Dr Sarah Oakley-Mudge, Director of Clinical Development. “With the only cGMP-certified manufacturing facility in Europe dedicated to producing peanut allergy immunotherapy for human use we believe we are well positioned to utilize this award to accelerate the development of CA002 into Phase 3 trials and towards commercialization”.